In a report issued on May 8, Gregory Renza from RBC Capital maintained a Buy rating on ACADIA Pharmaceuticals (ACAD), with a price target of $58.00. The company’s shares closed last Friday at $50.72, close to its 52-week high of $53.71.
According to TipRanks.com, Renza is a 5-star analyst with an average return of 51.8% and a 60.5% success rate. Renza covers the Healthcare sector, focusing on stocks such as Inovio Pharmaceuticals, Aptose Biosciences, and Aprea Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for ACADIA Pharmaceuticals with a $60.42 average price target, implying a 21.4% upside from current levels. In a report issued on May 5, Canaccord Genuity also maintained a Buy rating on the stock with a $56.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $53.71 and a one-year low of $21.56. Currently, ACADIA Pharmaceuticals has an average volume of 1.37M.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
